• Vaccine Name: MERS-CoV S vaccine adjuvanted with CpG and Alum
• Target Pathogen: MERS-CoV
• Target Disease: Middle East Respiratory Syndrome (MERS)
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• S from MERS-CoV gene engineering:
  • Type: Recombinant protein preparation
  • Description: The S spike protein was conjugated with CpG or Alum as a subunit MERS vaccine (Deng et al., 2018).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: The spike protein of middle east respiratory syndrome coronavirus adjuvanted with CpG and Alum provided protection against infection of MERS-CoV (Deng et al., 2018).

Mouse Response

• Host Strain: Balb/c
• Host gender: Female (Deng et al., 2018)
• Vaccination Protocol: Mice were given intramuscular immunizations at 4-week intervals of S protein + adjuvant at a dosage of 1 μg of S protein. (Deng et al., 2018)
• Immune Response: Induced S-specific neutralizing antibodies after 2 weeks, though titres were lower than in vaccine 5721. S-specific IgG tires were 10^5 at 6 weeks (after second dose), similar to titres of vaccine 5721. S-specific IgG titres did not increase after the third dosage. The IgG2a/IgG1 and IgG2b/IgG1 ratios were ~1. (Deng et al., 2018)